Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a pathologic diagnosis of malignancy~2. Patients with any radiographic evidence of bone metastases, including plain x-ray, bone scan, computed tomography (CT) scan, magnetic resonance imaging (MRI), or positron emission tomography (PET) scan~3. Patients with pain or dysaesthesia~4. Patients with a life expectancy of more than 3 months~5. Patients able to complete pain assessment and quality of life surveys~6. Patients with multiple osseous sites are eligible; however should not treat more than 3 separate radiation treatment fields concurrently.~7. Patients with surgery for osseous metastases are allowed.~Exclusion Criteria:~1. Patients with prior radiation therapy to the treatment site~2. Patients with a current, untreated spinal cord compression~3. Patients with a radiographic or pathologic fracture to the treatment site~4. Patients with painful metastases to hands and feet that need to be radiated on protocol~5. Patients previously treated with radioactive isotope (e.g. Sr89) within 30 days of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hypofractionated Radiation Therapy (Type: EXPERIMENTAL): Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row. Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
- One Radiation Therapy Treatment (Type: ACTIVE_COMPARATOR): 12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV). Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.

Based on this trial design, predict the completion outcome and termination type (if applicable).